You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盈康生命(300143.SZ)2020年度預盈1.3億-1.5億元 同比扭虧為盈
格隆匯 01-28 21:21

格隆匯 1 月 28日丨盈康生命(300143.SZ)公佈,預計2020年度歸屬於上市公司股東的淨利潤1.3億元-1.5億元,上年同期虧損70341.12萬元;扣除非經常性損益後的淨利潤1300萬元-1900萬元。業績變動原因如下:

1、歸屬於上市公司股東的淨利潤較上年同期扭虧為盈,主要是由於上年同期計提商譽減值準備7.29億元,致使上年同期經營業績出現虧損。

2020年,公司以“物聯網腫瘤治療綜合生態品牌”為定位,圍繞腫瘤治療綜合解決方案這一主線,堅持“一體兩翼”,從腫瘤治療設備和腫瘤治療服務兩個維度推進腫瘤治療康復領域全產業鏈的發展,腫瘤治療設備向“高”端發展,打造全球領先的腫瘤治療科技生態品牌;腫瘤治療服務向“寬”度發展,打造國內一流的腫瘤治療服務連鎖第一聯想度品牌。

醫療服務板塊(腫瘤治療服務)旗下醫院質控體系及運營能力持續升級迭代,打造“醫患合一”物聯網線上線下相融合的醫療生態,同時醫療設備板塊(腫瘤治療科技)始終堅持高端化、數字化和網絡化的戰略,致力於將瑪西普醫學科技發展(深圳)有限公司打造成全球領先的腫瘤治療科技生態品牌。

基於公司2020年度各主要業務板塊的經營業績及公司管理層對業績的評估與展望,初步預測公司2020年度不存在大額的商譽減值風險。

2、公司預計2020非經常性損益的金額約為1億元~1.3,主要系收購四川友誼醫院有限責任公司(“友誼醫院”)75%股權和收購友誼醫院25%股權交易對方2019年度業績補償所致。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account